Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Randomized Phase II Study of Erlotinib, Cisplatin and Radiotherapy Versus Cisplatin and Radiotherapy in Patients With Stage III and IV Squamous Cell Carcinoma of the Head and Neck.

Trial Profile

A Multicenter Randomized Phase II Study of Erlotinib, Cisplatin and Radiotherapy Versus Cisplatin and Radiotherapy in Patients With Stage III and IV Squamous Cell Carcinoma of the Head and Neck.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erlotinib (Primary) ; Cisplatin
  • Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Nasopharyngeal cancer; Oropharyngeal cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 Results of an exploratory analysis assessing racial disparity in oncologic and patient-reported quality of life presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 17 Jul 2012 Planned end date changed from 1 Jan 2013 to 1 Mar 2012 as reported by ClinicalTrials.gov.
    • 17 Jul 2012 Planned end date changed from 1 Jan 2013 to 1 Mar 2012 as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top